Adaura: Osimertinib Adjuvant Therapy In Egfr Mutated Nsclc

ADAURA: osimertinib adjuvant therapy in EGFR mutated NSCLC

ASCO 2023 Highlights on adjuvant osimertinib in resected EGFR mutated NSCLC: The ADAURA trial

European Society for Medical Oncology (ESMO)

ESMO 2020 Highlights on adjuvant osimertinib for EGFR mutated NSCLC: The ADAURA study

European Society for Medical Oncology (ESMO)

ADAURA: osimertinib adjuvant therapy on CNS disease recurrence

ADAURA: the benefit of adjuvant osimertinib

Is adjuvant chemotherapy in EGFR mutated NSCLC still required?

Adjuvant Osimertinib and Advanced EGFR-Mutated NSCLC | NEJM

ADAURA results: Adjuvant osimertinib for EGFRm non-small cell lung cancer

Updates from ADAURA: continued DFS benefit with osimertinib vs. placebo

Osimertinib + ipilimumab in EGFR-mutated NSCLC

Dr. Herbst on the Benefit of Adjuvant Osimertinib in EGFR-Mutant NSCLC

Reflections on the ADAURA study

Adjuvant osimertinib in resected EGFRm NSCLC: the OS data from the ADAURA trial

Osimertinib adjuvant therapy in patients with early stage EGFR mutated NSCLC after tumour resection

ADAURA Trial: Osimertinib for Early Stage EGFR+ NSCLC - 2022 Program: Targeted Therapies Forum

GRACE - Global Resource for Advancing Cancer Education

ADAURA: osimertinib post-tumor resection in NSCLC

ADAURA Study Demonstrates Promising Efficacy for Osimertinib in EGFR-Mutant NSCLC

Targeted Oncology

Dr. Levy on the DFS Benefit Achieved With Adjuvant Osimertinib in EGFR+ NSCLC

Osimertinib after surgery significantly improves survival in resected EGFR-mutated NSCLC

ADAURA: Osimertinib as Adjuvant Therapy in Stage III EGFR+ NSCLC